Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy

Published:2014-11-03 Issue:1 Volume:24 Page:125-132
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Bronte Giuseppe,Lo Vullo Francesca,Pernice Gianfranco,Galvano Antonio,Fiorentino Eugenio,Cicero Giuseppe,Bazan Viviana,Rolfo Christian,Russo Antonio

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/13543784.2015.979284

Reference29 articles.

1. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

2. Cancer incidence and mortality in Europe, 2004

3. The 7th Edition of TNM in Lung Cancer: What Now?

4. Non-Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics and New Frontiers

5. Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial;npj Precision Oncology;2022-03-01

2. Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer;Scientific Reports;2018-01-19

3. Biology and clinical significance of circulating tumor cell subpopulations in lung cancer;Translational Lung Cancer Research;2017-08

4. Challenges of Applying Targeted Nanostructures with Multifunctional Properties in Cancer Treatments;Nanoscience and Nanotechnology for Human Health;2016-12-02

5. Profile of farletuzumab and its potential in the treatment of solid tumors;OncoTargets and Therapy;2016-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3